Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for US$5.4bil, one of a string of purchases that Starboard considers to have delivered poor results, the person said.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Pfizer got a reprieve in late January when Starboard did not nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026. Among Pfizer ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Pfizer appears to have dodged a proxy battle with activist investor Starboard Value, which has a roughly $1 billion stake in the pharmaceutical giant, for now. The deadline passed for nominating ...

That Pfizer’s turnaround is already well underway is reflected by the fact that activist investor Starboard Value, led by Jeffrey Smith, wisely chose not to nominate any dissident directors to ...